AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02946671 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab (3.0 mg/kg) is administered.
Study NCT03498469 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standardized reintegration package
Description: Participants assigned to this comparison arm will receive a standardized reintegration package that includes individualized case management support and a reunification cash grant Individualized case management will consist of a caseworker-developed individualized care plan with routine caseworker visits at the household level. Home visitation will begin during the family assessment and preparation stages and continue throughout the 15-month post-reunification follow-up period. For the cash grant, the family of each enrolled child will receive a reunification cash grant in the Ugandan Shilling equivalent of $125, administered in two equal disbursements. It is designed to offset the cost of child care.
Study NCT03498469 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced reintegration package
Description: Participants assigned to this arm will receive an enhanced reintegration package that consists of the parenting program, individualized case management, and the reunification grant. will be delivered at the household level by project trained parenting facilitators. The program will consist of approximately 13 bi-weekly sessions, which will be delivered over the course of 7 months. The individualized case management and the reunification grant will be similar to those in the comparison arm.
Study NCT02811718 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stress Management Group 1
Description: Subjects will attend group stress management sessions via Skype once weekly for 8 weeks and learn stress/NF symptoms managements techniques.
Study NCT02811718 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stress Management Group 2
Description: Subjects will attend group stress management sessions via Skype once weekly for 8 weeks and learn stress/NF symptoms managements techniques.
Study NCT01322191 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Morphine
Description: A single dose of morphine 0.1 mg/kg infused by syringe pump over 10 minutes; urine and blood sample frozen at -80 degrees Celsius
Study NCT01446146 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Informed decision making
Description: 40 minute session with a clinician. Participants will learn about the available PTSD treatment options and will be given a decision aid with more information.
Study NCT01446146 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo session
Description: Participant will complete clinician-administered measures in a 40-minute session.
Study NCT02503319 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid
Description: 2 vials ( =1 gram) of Tranexamic Acid oral administered within 5 minutes from the delivery (third stage after labor)~2 vials (=1 gram ) of Tranexamic Acid administered slow intravenous infusion within 5 minutes from the delivery (third stage after labor)
Study NCT02503319 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid
Description: 2 vials ( =1 gram) of Tranexamic Acid slow intravenous infusion administered within 5 minutes from the delivery (third stage after labor)
Study NCT02503319 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxytocin
Description: 2 vials (=10 IU/International Unit) of oxytocin administered intramuscularly within 5 minutes from the delivery (third stage after labor)
Study NCT03658642 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Clinical Decision Support (CDS)
Description: This clinical decision support tool will improve the clinician's ability to identify those with OUD, initiate BUP and refer the patient to ongoing Medication Assisted Treatment (MAT)
Study NCT04071301 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TENA SmartCare Change Indicator
Description: Each participating subject will be provided with a Change Indicator and absorbent products for the duration of the investigation. Nine types of absorbent products will be used to collect real-life measurement data in order to assess the mathematical algorithms involved in the TENA SmartCare Change Indicator. Each participating subject will be allocated to the type(s) that are considered most suitable.~Gateways will be placed in the resident's rooms as well as in common areas, this to enable full measurement registration.
Study NCT02769442 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Terumo SurFlash Plus catheter
Study NCT02769442 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: BD Insyte Autoguard catheter
Study NCT02214511 — intervention group
Intervention type: BEHAVIORAL
Intervention: emotional facial stimuli
Description: Subjects watch passively dynamic facial emotions obtained by emotionnal faces photos morphing. Their rapid facial reactions are recorded by faciel EMG device as eye movement by occulometric device.
Study NCT02214511 — intervention group
Intervention type: BEHAVIORAL
Intervention: Cyberball game
Description: Ball tossing computer game to manipulate social inclusion status : rejection or inclusion. Social behavior, social pain and inflammatory modification will be assessed after the game.
Study NCT03917745 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: eHealth mindfulness intervention
Description: The web-based intervention consists of eight sessions including psycho-education about the mechanisms of stress, coping and relaxation, especially related to pregnancy, practicing mindfulness skills (i.e. mindful breathing, mindful moving, observing and letting-go of thoughts and emotions with a non-judgmental attitude), sharing experiences, and doing home assignments. The sessions have been developed specifically for pregnant women and acknowledge pregnancy-related distress. An online coach will review questions and home assignments of the participants. Women will start the training at 16 weeks gestation.
Study NCT02932930 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: QLB bloc
Study NCT02932930 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: QLB bloc
Study NCT02932930 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.2% Ropivacaine
Description: 0,2ml/kg of 0,2% ropivacaine
Study NCT02932930 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% normal saline
Description: 0,2ml/kg of 0.9% normal saline
Study NCT06106867 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: External pressure to the palm
Description: During the 5-6 cm, 7-8 cm, and 9-10 cm cervical dilatation stages of the labor process, palm external pressure was applied to the pregnant women in the experimental group.
Study NCT00662597 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASA404
Study NCT00662597 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00662597 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: carboplatin
Study NCT00662597 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Study NCT00662597 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Paclitaxel
Study NCT00662597 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Study NCT04901923 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACP-196
Description: Participants will receive ACP-196 oral capsule(s) in all parts.
Study NCT04901923 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Description: Participants will receive itraconazole 200 mg capsules BID from Days 4 to 8 with meals and then 200 mg capsule QD on Day 9 under fasting state.
Study NCT03577847 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Rural CT scanning
Description: Rural computer tomography for acute stroke
Study NCT01684189 — intervention group
Intervention type: OTHER
Intervention: Patient registry
Description: Patient registry without study intervention
Study NCT03768622 — intervention group
Intervention type: PROCEDURE
Intervention: surgery for pertrochanteric femoral fracture
Description: surgical treatment for proximal femoral fracture with intramedullary nail type Gamma® Nail or similar in case of pertrochanteric fractures
Study NCT03768622 — intervention group
Intervention type: PROCEDURE
Intervention: surgery for femoral neck fracture
Description: surgical treatment for proximal femoral fracture with a partial hip arthroplasty in case of femoral neck fractures
Study NCT02125279 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcitriol
Study NCT01627262 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mesalamine
Description: 3x1000mg mesalamine granules per day
Study NCT01627262 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 3x1000mg placebo granules per day
Study NCT00945672 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PF-04360365 10 mg/kg
Description: 10 mg/kg every 90 days (5 total doses)
Study NCT00945672 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PF-04360365 7.5 mg/kg
Description: 10 mg/kg loading dose followed by 7.5 mg/kg monthly maintenance dosing (total of 13 doses)
Study NCT00945672 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo administered every 90 days or monthly to match experimental treatment arms.
Study NCT01109134 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tirofiban intracoronary bolus-only
Description: administer tirofiban bolus intracoronary during primary percutaneous coronary intervention with no additional maintenance infusion
Study NCT01109134 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tirofiban intravenous bolus plus infusion
Description: administer tirofiban bolus intravenously and maintain infusion for up to 18 hours
Study NCT01590316 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cerebral NIRS oximetry
Description: Cerebral NIRS oximetry during the first 72 hours of life.
Study NCT03290391 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rapid ART initiation
Description: The infectionist will streamline the approval with the ultimate goal of starting participants on ART while they are still hospitalized at the City Addiction Hospital.
Study NCT03290391 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pharmacotherapy for opioid use disorder
Description: Thirteen months of naltrexone treatment for opioid use disorder (injection at baseline, followed by 4 implants).
Study NCT03290391 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Strengths-based HIV case management
Description: Strengths-based case management: 10 sessions over 12 months in which a trained case manager (CM) meets individually with patients to motivate them to engage in HIV medical care by supporting the recognition of their own strengths to make positive changes in their lives and ultimately improve their HIV outcomes.
Study NCT00599742 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Balance training
Description: Physical exercise of balance. The training will last 7 weeks, twice per week, 1 hour per session.
Study NCT00599742 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Motor training
Description: Motor exercise of power and flexibility. The training will last 7 weeks, twice per week, 1 hour per session.
Study NCT03633916 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Classroom sensitization session
Description: A one-off classroom information and engagement session will be delivered in addition to school-level sensitization activities. Individual classroom sessions will be conducted by a 'lay' counsellor with support from a researcher.~The classroom session will start with a short animated video which provides age-appropriate information about types, causes, impacts and ways of coping with common mental health problems. The video will be followed by a guided group discussion, structured around a standardized script that builds on the topics covered in the video. In case of technical difficulties that may prevent the video from being shown, a flipchart based on still illustrations from the video will be used.~At the end of the session, students will be handed a self-referral form which includes normalizing information and question-based prompts to assist with self-identification of mental health problems.
Study NCT03633916 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: School-level sensitization activities
Description: The control condition intervention will comprise sensitization activities conducted at the whole school level. These activities will include:~1. Posters containing information about the school counselling program and referral pathways will be displayed in prominent locations at each school.~2. A drop-box for student self-referral slips will be set up in a prominent location at each school.~3. Information meetings with teachers and the principal will be conducted at each school from the beginning of the trial.
Study NCT03633916 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: School-level sensitization activities
Description: The control condition intervention will comprise sensitization activities conducted at the whole school level. These activities will include:~1. Posters containing information about the school counselling program and referral pathways will be displayed in prominent locations at each school.~2. A drop-box for student self-referral slips will be set up in a prominent location at each school.~3. Information meetings with teachers and the principal will be conducted at each school from the beginning of the trial.
Study NCT02494648 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: POWERbreathe Fitness Plus, (POWERbreathe International Ltd, UK) [Inspiratory muscles strengthening]
Description: CAD patients participated in a 6-week (20 sessions of training) resistive inspiratory muscle training (RIMT) program for 10 minutes twice daily at a training intensity of 70% of maximum inspiratory pressure (MIP).
Study NCT02494648 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control
Study NCT02538406 — intervention group
Intervention type: OTHER
Intervention: Segmental withdrawal
Description: Interventional group will have at least 3 minutes dedicated to the right side of the colon during segmental withdrawal.
Study NCT00501137 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: HPV (Human Papillomavirus) Vaccine
Description: HPV (Human Papillomavirus) Vaccine received by all participants in groups 1, 2 and 3 according to the arm
Study NCT00768287 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IB1001
Description: Study Part 1: Randomized, double-blind, cross-over study with IB1001 and nonacog alfa; Study Part 2: Non-randomized, open-label evaluation of prophylaxis and on demand IB1001; Surgical Sub-study: Open-label evaluation of IB1001 during major surgery
Study NCT00768287 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: nonacog alfa
Description: Study Part 1: Randomized, double-blind, cross-over study with IB1001 and nonacog alfa
Study NCT01357005 — intervention group
Intervention type: OTHER
Intervention: No intervention would be provided in this research
Description: No intervention would be provided in this research, but need to draw blood
Study NCT02652702 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: circular stapler-assisted colostomy
Description: procedure:circular stapler-assisted colostomy device:circular stapler
Study NCT02652702 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: conventional hand-stitching colostomy
Description: procedure:hand-stitching colostomy
Study NCT03056014 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: N-acetyl cysteine
Description: giving varying doses of NAC in order to determine which reduces oxidative stress.
Study NCT03056014 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: omega 6 Fish oil ( PUFA)
Description: giving varying doses of PUFA in order to determine which reduces oxidative stress.
Study NCT03056014 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: L-alanine placebo pill to determine if effect is supplement related or random effect.
Study NCT02710227 — intervention group
Intervention type: OTHER
Intervention: (PSQI), (STQ).
Description: Sleep quality, sleep timing parameters and circadian preference were evaluated using (PSQI), (STQ).
Study NCT03272906 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Anodal transcranial direct current stimulation
Description: 2 mA of A-tDCS stimulation is induced between two 5 cm x 7 cm saline soaked sponges where one sponge (anode: A-tDCS) is placed on the scalp over the targeted cortical region. Ramping up of the current to 2 mA occurs over 30 seconds to allow participants to habituate to the tingling sensation. A-tDCS stimulation will be active only in the first 20 minutes of the 60-minute treatment session.
Study NCT03272906 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham transcranial direct current stimulation
Description: 2 mA of A-tDCS stimulation is induced between two 5 cm x 7 cm saline soaked sponges where one sponge (anode: A-tDCS) is placed on the scalp over the targeted cortical region. Ramping up of the current to 2 mA occurs over 30 seconds to allow participants to habituate to the tingling sensation. Then, the current will be ramped back down to 0 mA in the sham condition.
Study NCT03272906 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Speech-language therapy
Description: Therapy tasks will be determined by the clinician on an individualized basis and will not be affected by this research protocol. The only difference between the clinical therapy that is normally provided in the clinic and this research paradigm is the application of tDCS electrodes during therapy. Therapist is blinded to stimulation type.
Study NCT03272906 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Speech-language therapy
Description: Therapy tasks will be determined by the clinician on an individualized basis and will not be affected by this research protocol. The only difference between the clinical therapy that is normally provided in the clinic and this research paradigm is the application of tDCS electrodes during therapy. Therapist is blinded to stimulation type.
Study NCT04315805 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Integrative Yoga Therapy
Description: Yoga therapy will be based on personalised care consisting of Yoga relaxing posture, strengthening exercise, Yoga breathing, meditative psychotherapy, sound and imagery yoga practices, relaxation, yoga diet and life style management.
Study NCT01592045 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ch14.18 -NCI
Description: 25 mg/m\^2/day IV for four consecutive days
Study NCT01592045 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ch14.18-UTC
Description: 17.5 mg/m\^2/day IV for four consecutive days
Study NCT01592045 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)
Description: GM-CSF will be administered SC at a dose of 250 mcg/m\^2/day for 14 days during Courses 1, 3, and 5.
Study NCT01592045 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Aldesleukin (IL-2)
Description: Aldesleukin (IL-2) will be administered IV at a dose of 3 MIU/m\^2/day for the first week and at a dose of 4.5 MIU/m\^2/day for the second week during Courses 2 and 4.
Study NCT01592045 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isotretinoin
Description: Isotretinoin (13-cis-retinoic acid; ISOT) will be administered by mouth over six courses as follows:~If weight > 12 kg: 80 mg/m\^2/dose twice daily (total daily dose is 160 mg/m\^2/day, divided twice daily).~If weight ≤ 12 kg: 2.67 mg/kg/dose twice daily (total daily dose is 5.33 mg/kg/day, divided twice daily).
Study NCT01395004 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2110183
Description: GSK2110183 was orally administered at 125 mg once daily.
Study NCT04966026 — intervention group
Intervention type: OTHER
Intervention: No inervention
Description: No inervention
Study NCT05457751 — intervention group
Intervention type: PROCEDURE
Intervention: Rocuronium injection pain
Description: 1: no reaction, 2: movement only in the ankle, 3: movement or withdrawal only in the arm (shoulder and ankle), 4: diffuse reaction (movement or withdrawal in more than one extremity, coughing and holding breath
Study NCT04249570 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Povidone iodine
Study NCT03728751 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dry needling
Description: Paravertebral dry needling C7-T4. Total of 8 needles.
Study NCT03510897 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: teprasiran
Description: IV injection
Study NCT01415934 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: discontinue statins
Description: patients will be randomized to either continue taking statins or discontinue.
Study NCT03510897 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: isotonic saline
Study NCT03916406 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF 06835919
Description: 300 mg
Study NCT03916406 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: 7.5 mg
Study NCT02579590 — intervention group
Intervention type: DRUG
Intervention: Depot Medroxyprogesterone Acetate 150 mg
Description: the DMPA user where they are using Depot Medroxyprogesterone Acetate 150 mg (DMPA; Phrmcia) injection every 3 month
Study NCT02579590 — intervention group
Intervention type: DRUG
Intervention: Implanon( 68 mg etonogestrel implant)
Description: where they are using etonogestrel 68 mg implant (Implanon; Organon)